Biotechnology
Cancer Prevention
Health
Exact Sciences
$96.889876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$96.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.88 (3.06%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Exact Sciences and other stocks, options, ETFs, and crypto commission-free!
About
Exact Sciences Corporation Common Stock, also called Exact Sciences, is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. Read More The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Employees
1,977
Headquarters
Madison, Wisconsin
Founded
1995
Market Cap
12.51B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.99M
High Today
$97.43
Low Today
$94.62
Open Price
$94.62
Volume
498.49K
52 Week High
$105.28
52 Week Low
$47.78
Collections
Biotechnology
Cancer Prevention
Health
Technology
News
NasdaqMay 3
EXAS Crosses Above Average Analyst Target
In recent trading, shares of EXACT Sciences Corp. (Symbol: EXAS) have crossed above the average analyst 12-month target price of $101.12, changing hands for $101.65/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the...
Price Paid on Robinhood
59% Higher
Right Now
52 Week Low
$47.78
Average Price Paid
$61.08
52 Week High
$105.28
Earnings
-$0.65
-$0.49
-$0.34
-$0.18
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 31, After Hours